Catalyst

Slingshot members are tracking this event:

Gilead Announces CHMP Adopts Positive Opinion on Duscovy for Treatment of HIV

Source Link:
http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2143753

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details The Committee for Medicinal Products for Human Use (CHMP)  adopted a positive opinion on Gileads MAA for fixed dose combination Duscovy (emtricitabine/tenofovir alafenamide) for HIV.  The European Commission will now review the MAA with the recommendation from CHMP.
http://investors.gil...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Feb 26, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Chmp, Positive Opinion, Duscovy, Hiv, Tenofovir Alafenamide, Emtricitabine
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.